BALLARD PARTNERS for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Advice and guidance related to supply chains and trade tariffs.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s commercial and financial success.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BALLARD | — |
| HUNTER MORGEN | Policy Advisor, Office of Policy Planning, U.S. State Dept. (2017); Deputy Director, Office of Trade & Manufacturing Policy, WH (2017-2018); Special Assistant to the President, Office of the Senior Advisor for Policy, WH (2018-2020) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.